ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

Johanna C. Bendell, MD
Published: Tuesday, Nov 28, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable (MSS).

Bendell says that 95% of patients with metastatic CRC are not microsatellite high, and treatments for them must be developed. Preliminary results of combinations with immunotherapy have shown promising response rates.

The combination of the PD-1 inhibitor atezolizumab (Tecentriq) with the MEK inhibitor cobimetinib (Cotellic) showed impressive preliminary results, and the combination has now moved into a randomized phase III global study.
 


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable (MSS).

Bendell says that 95% of patients with metastatic CRC are not microsatellite high, and treatments for them must be developed. Preliminary results of combinations with immunotherapy have shown promising response rates.

The combination of the PD-1 inhibitor atezolizumab (Tecentriq) with the MEK inhibitor cobimetinib (Cotellic) showed impressive preliminary results, and the combination has now moved into a randomized phase III global study.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x